Q4 2020 Cytokinetics Inc Earnings Call Transcript
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Fourth Quarter 2020 Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)
I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of our 2021 priorities considering company performance in 2020. Then Fady Malik, our EVP of Research and Development, will provide a more detailed update on omecamtiv mecarbil, including prospective on recently presented supplemental analyses from GALACTIC-HF, the positive Phase III clinical trial of omecamtiv mecarbil as well as progress on METEORIC-HF, the second Phase III clinical trial of omecamtiv mecarbil.
Next, Stuart Kupfer, our SVP and Chief Medical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |